By IDSE News Staff
The FDA approved aztreonam-avibactam (Emblaveo, AbbVie), the first and only fixed-dose, IV monobactam/beta-lactamase inhibitor combination antibiotic to be used with metronidazole, to treat complicated intraabdominal infections (cIAIs), including those caused by the following susceptible gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex and Serratia marcescens.
Approval of this